Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.30 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15339921 | 0.83 | MRGPRX4 (0.40) | MRGPRX4HDAC1HDAC6ACHESLC6A2 | |
| SCHEMBL177568 | 0.83 | HTR2A (0.40) | ACHESLC6A4RAB9AKMT2A | |
| SCHEMBL177743 | 0.79 | SOS1 (0.41) | SLC6A4 | |
| SCHEMBL177356 | 0.79 | TDP1 (0.44) | SLC6A4NPC1ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL29804592 | 0.79 | TDP1 (0.44) | SLC6A4NPC1ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL9979977 | 0.77 | MRGPRX4 (0.41) | MRGPRX4HDAC1HDAC6ACHESLC6A2 | |
| SCHEMBL171839 | 0.77 | CYP1A2 (0.47) | MRGPRX4ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13130874 | 0.76 | MRGPRX4 (0.40) | MRGPRX4HDAC1HDAC6ACHESLC6A2 | |
| Ammonia Solution, Strong SCHEMBL27831764 | 0.76 | CYP1A2 (0.46) | MRGPRX4ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23218 | 0.75 | RAB9A (0.46) | NPC1ALDH1A1RAB9AL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302041-A1 | PLANT DISEASE CONTROL METHOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-4541188-A1 | PLANT DISEASE CONTROL METHOD | Sumitomo Chemical Company, Limited (JP) | 2025-04-23 | — | — | EP | disclosed |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2019-03-07 | — | — | US | disclosed |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9737506-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9205074-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2015-05-28 | — | — | US | disclosed |
| EP-1636206-B1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | EP | disclosed |
| EP-1831217-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2007-09-12 | — | — | EP | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| WO-2007016155-A2 | NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006135993-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006069805-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2006-07-06 | — | — | WO | disclosed |
| EP-1636206-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-20050143375-A1 | Imidazole derivatives | ROCHE PALO ALTO LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004108701-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248888-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1D, HTR1B | MRGPRX4 2558/4885HDAC1 237/4885HDAC6 605/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | MRGPRX4 2231/4885HDAC1 274/4885HDAC6 571/4885 |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | MRGPRX4 2231/4885HDAC1 274/4885HDAC6 571/4885 |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | MRGPRX4 2231/4885HDAC1 274/4885HDAC6 571/4885 |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | MRGPRX4 2231/4885HDAC1 274/4885HDAC6 571/4885 |
| US-20040248888-A1 | Imidazole derivatives | GRIK5, GRM5, GRIN2B | MRGPRX4 484/4885HDAC1 429/4885HDAC6 1234/4885 |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | MRGPRX4 2231/4885HDAC1 274/4885HDAC6 571/4885 |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | MRGPRX4 2231/4885HDAC1 274/4885HDAC6 571/4885 |
| US-20250302041-A1 | PLANT DISEASE CONTROL METHOD | H1-3, RER1, C5 | MRGPRX4 1158/4885HDAC1 2098/4885HDAC6 2372/4885 |
| US-20050143375-A1 | Imidazole derivatives | GRM5, GRIK5, GRM2 | MRGPRX4 124/4885HDAC1 429/4885HDAC6 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.